Introduction

Cryo-Fluorescence Tomography (CFT) is a preclinical imaging technology that bridges the gap between in vivo modalities such as PET/SPECT, MRI, FLI, and bioluminescence imaging, and downstream assays like histology, immunohistochemistry, PCR, and other molecular or biochemical analyses.

Powered by the EMIT Imaging Xerra™ Platform, CFT generates co-registered 3D datasets by combining anatomical imaging with multi-spectral fluorescence. With up to 20 μm resolution and nanomolar sensitivity, it provides whole-body imaging of biodistribution, expression, and molecular processes. As an ex vivo imaging method, CFT sections the sample and images the block face after each section is removed. This produces high resolution, high sensitivity images that preserve molecular and structural detail.

CFT achieves molecular insights comparable to nuclear imaging without the complexity or safety considerations of radioactive tracers. This integrated capability supports efficient preclinical discovery by accelerating data collection, improving molecular and anatomical understanding, and informing translational research. Applications include:

• Whole-body biodistribution of biologics, delivery systems, and nanoparticles
• Detection and targeting of gene and cell therapy vectors
• Visualization of biomarkers and disease models (e.g., immune cell trafficking, tumor heterogeneity)
• Evaluation of treatment response and PK/PD relationships
• Multiplexed imaging of multiple probes or therapies for co-localization studies

By providing an integrated perspective from the whole animal to sub-organ levels, CFT has become a powerful decision-making tool in basic science and translational drug discovery research. It not only confirms whether therapies reach intended targets but also reveals unexpected off-target accumulation that may be missed with conventional approaches.

Following these tips and tricks, users can optimize their fluorescence studies when conducting in vivo work with a CFT imaging endpoint. Here, we focus on study design and sample preparation to specifically optimize CFT.

Experimental Design and Controls

Pilot studies often begin with a single animal per experimental group to establish feasibility and optimize imaging parameters. Additional replicates can then be added in subsequent studies to strengthen statistical power, consistency, reproducibility, and translational relevance. Proper experimental controls are essential for accurate interpretation of fluorescence signals. To account for tissue autofluorescence, control animals without injected fluorescence compound should be included, and in certain studies evaluation of free dye may be prudent. In addition, EMIT Imaging incorporates a dilution of fluorescence standards in the block to normalize signals across blocks and to estimate the concentration of drug in tissues.

Reporter Genes and Fluorophore-Labeled Agents

CFT can image both fluorescent reporter proteins and fluorophore-labeled agents spanning from 470 to 800 nm. Fluorescent reporter proteins provide a readout of transgene expression at the protein level following delivery by systems such as AAVs and LNPs. Many options exist across the spectrum, including eGFP, mGreenLantern, tdTomato, mCherry, mKate, Katushka, and iRFP713.

Fluorophore-labeled agents support interrogation of pathology, ADME-Tox, and therapeutic efficacy across diverse modalities. These include molecular probes that report on biological processes, such as ligands, oligonucleotides, peptides, carbohydrates, and antibodies, as well as labeled small molecule or biologic drugs formulated to evaluate biodistribution and pharmacokinetic behavior. Agents can be sourced commercially, synthesized in-house, or formulated through contract research organizations.

Fluorophore Conjugation and Optimization

Successful fluorescence-based imaging depends on efficient and stable probe labeling. A variety of chemistries can be employed, including N-hydroxysuccinimidyl (NHS) ester coupling to free amines, maleimide-thiol reactions, azide-alkyne click chemistry, direct labeling during solid-phase synthesis, and enzymatic labeling. The selection of a labeling strategy depends on factors such as probe type, available reactive groups, and whether site-specific labeling is needed. For example, NHS ester chemistry can be applied to lysine residues, while click chemistry may be preferred for targeted conjugation.

Optimizing reaction conditions is essential to preserve both the stability and biological activity of the probe. Reactive fluorophore derivatives are readily available from multiple suppliers, either as components of labeling kits or as bulk reagents suitable for custom conjugation protocols. When in-house expertise or resources are limited, conjugation services can also be outsourced to ensure consistent probe performance and quality.

The degree of labeling (DOL) is an essential part of probe preparation. As a starting point, a DOL of approximately 1 is typical for low-molecular-weight compounds (e.g., peptides and oligonucleotides), while a DOL of approximately 2 is often suitable for antibodies and high-molecular-weight compounds. The optimal ratio is probe-specific and should be determined empirically, as labeling density can influence performance. Excessive labeling may reduce binding specificity and increase off-target interactions, whereas insufficient labeling can lead to weak or undetectable signal. For proteins and antibodies, UV-Vis spectrophotometry is commonly used, applying known extinction coefficients and appropriate correction factors. For small molecules, peptides, and oligonucleotides, LC-MS can provide more accurate measurements, as exact mass determination enables direct calculation of labeling stoichiometry. It is recommended to inject approximately 10 nmol (range of 5-20 nmol) of fluorophore into animals to ensure sufficient fluorescence signal for CFT.

After labeling, removal of unreacted free dye is critical to avoid high background signal and misinterpretation of biodistribution results. Unlike bioconjugation techniques used for other tissue imaging applications, there is no wash step in the CFT process that removes free dye, so it is important to target greater than 95% fluoro-chemical purity (akin to radiolabeling procedures). Common cleanup methods include size-exclusion chromatography on spin columns, dialysis, and HPLC/FPLC. In most cases, a spin column is sufficient. The choice of purification approach should be based on the size, solubility, and other chemical characteristics of both the labeled probe and the unreacted dye. It is also important to confirm functionality post-labeling, e.g., perform cell binding studies to confirm the labeled compound still binds to its target.

Fluorophore Selection for Multiplexed Imaging

When selecting fluorophores, far-red and NIR fluorophores (e.g., Cy7, Alexa Fluor 750/790, IRDye 800, ICG, and others) offer reduced background tissue autofluorescence and animal-chow fluorescence, which can confound image interpretation. When experimental constraints allow, these wavelengths are recommended.

Xerra CFT systems are well-suited for multiplexed fluorescence detection. Multiple excitation lasers and emission filters support concurrent imaging of up to four spectrally distinct fluorophores. Users can take advantage of multiplexed detection for evaluation of multiple targets or co-localization of targets and drug candidates. To optimize results, fluorophores should be chosen based on non-overlapping emission spectra and compatibility with the system's filter sets.

Diet and Environmental Considerations

Diet selection is a critical component that can drastically impact the presence of autofluorescence when imaging. Standard rodent diets containing alfalfa, dyes, and other additives can introduce strong background autofluorescence in the gastrointestinal tract, which can interfere with detection of the signal of interest. To minimize this, animals should be switched to a chow suitable for the imaging channel of that study at least 7-10 days before euthanasia and freezing. This dietary adjustment reduces gut autofluorescence and improves contrast, particularly for studies relying on red-shifted fluorophores or low-abundance probes.

Careful chow selection is one of the simplest ways researchers can directly control the quality of their CFT data. By reducing unwanted background, it ensures higher sensitivity and enables clearer localization of probes.

Download poster (PDF) Evaluation of Rodent Diets for Minimizing Abdominal Background Fluorescence EMIT Imaging study, WMIC 2024

Timepoint Selection and Sample Numbers

The choice of imaging timepoints should be guided by the biology of the probe and the scientific question. Pharmacokinetic properties, target engagement kinetics, and clearance pathways all influence when signal is most informative. Collecting multiple timepoints can reveal the dynamics of uptake, retention, and clearance, providing a more complete picture of biodistribution than a single endpoint. Where a study is exploratory, a broader spread of timepoints helps identify the window of peak specific signal relative to background.

Sample numbers should balance statistical rigor with the exploratory nature of the study. Early feasibility work may use minimal replicates, while confirmatory studies benefit from additional animals to support reproducibility and translational relevance.

Sample Preparation, Perfusion, and Freezing

Consistent, careful sample preparation is essential for high quality CFT data. Where blood-pool signal or residual circulating probe would confound interpretation, transcardial perfusion with saline (optionally followed by a fixative) clears the vasculature and reduces background. Perfusion should be tailored to the probe and the tissues of interest.

After collection, samples must be frozen in a way that preserves morphology and fluorescence. Embedding in an optimal cutting temperature (OCT) style medium and freezing in a controlled manner avoids cracking and freeze artifacts. Rapid, even freezing preserves structural detail and prevents ice crystal formation that can distort tissue. Frozen blocks should be stored and transported at stable low temperatures to maintain both anatomical integrity and fluorescent signal until imaging.